These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 22583109)

  • 1. Improved outlook on HIV-1 prevention and vaccine development.
    Vasan S; Michael NL
    Expert Opin Biol Ther; 2012 Aug; 12(8):983-94. PubMed ID: 22583109
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human immunodeficiency virus (HIV) immunopathogenesis and vaccine development: a review.
    Girard MP; Osmanov S; Assossou OM; Kieny MP
    Vaccine; 2011 Aug; 29(37):6191-218. PubMed ID: 21718747
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current views on the potential for development of a HIV vaccine.
    Cohen KW; Frahm N
    Expert Opin Biol Ther; 2017 Mar; 17(3):295-303. PubMed ID: 28095712
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Future paths for HIV vaccine research: Exploiting results from recent clinical trials and current scientific advances.
    Bansal GP; Malaspina A; Flores J
    Curr Opin Mol Ther; 2010 Feb; 12(1):39-46. PubMed ID: 20140815
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HIV Vaccine Efficacy Trials: RV144 and Beyond.
    Heger E; Schuetz A; Vasan S
    Adv Exp Med Biol; 2018; 1075():3-30. PubMed ID: 30030787
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Progress and obstacles in the development of an AIDS vaccine.
    Letvin NL
    Nat Rev Immunol; 2006 Dec; 6(12):930-9. PubMed ID: 17124514
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The potential impact of a moderately effective HIV vaccine with rapidly waning protection in South Africa and Thailand.
    Andersson KM; Stover J
    Vaccine; 2011 Aug; 29(36):6092-9. PubMed ID: 21703322
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Vaccines against HIV].
    Holm-Hansen C
    Tidsskr Nor Laegeforen; 2006 Nov; 126(23):3117-20. PubMed ID: 17160118
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Accelerating the development of a safe and effective HIV vaccine: HIV vaccine case study for the Decade of Vaccines.
    Koff WC; Russell ND; Walport M; Feinberg MB; Shiver JW; Karim SA; Walker BD; McGlynn MG; Nweneka CV; Nabel GJ
    Vaccine; 2013 Apr; 31 Suppl 2():B204-8. PubMed ID: 23598483
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Challenges in the development of an effective HIV vaccine: current approaches and future directions.
    Klein E; Ho RJ
    Clin Ther; 2000 Mar; 22(3):295-314; discussion 265. PubMed ID: 10963285
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expected epidemiological impacts of introducing an HIV vaccine in Thailand: a model-based analysis.
    Schneider K; Kerr CC; Hoare A; Wilson DP
    Vaccine; 2011 Aug; 29(36):6086-91. PubMed ID: 21723902
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of an epitope-based HIV-1 vaccine strategy from HIV-1 lipopeptide to dendritic-based vaccines.
    Surenaud M; Lacabaratz C; Zurawski G; Lévy Y; Lelièvre JD
    Expert Rev Vaccines; 2017 Oct; 16(10):955-972. PubMed ID: 28879788
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand.
    Pitisuttithum P; Gilbert P; Gurwith M; Heyward W; Martin M; van Griensven F; Hu D; Tappero JW; Choopanya K;
    J Infect Dis; 2006 Dec; 194(12):1661-71. PubMed ID: 17109337
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New concepts in HIV-1 vaccine development.
    Stephenson KE; D'Couto HT; Barouch DH
    Curr Opin Immunol; 2016 Aug; 41():39-46. PubMed ID: 27268856
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel strategies toward the development of an effective vaccine to prevent human immunodeficiency virus infection or acquired immunodeficiency virus.
    Ensoli B; Cafaro A
    AIDS Clin Rev; 2000-2001; ():23-61. PubMed ID: 10999215
    [No Abstract]   [Full Text] [Related]  

  • 16. HIV vaccine efficacy trials: A brief history, and options for going forward.
    McKinnon LR; Card CM;
    AIDS Rev; 2010; 12(4):209-17. PubMed ID: 21179185
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic vaccination against HIV: current progress and future possibilities.
    Puls RL; Emery S
    Clin Sci (Lond); 2006 Jan; 110(1):59-71. PubMed ID: 16336205
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Extended evaluation of the virologic, immunologic, and clinical course of volunteers who acquired HIV-1 infection in a phase III vaccine trial of ALVAC-HIV and AIDSVAX B/E.
    Rerks-Ngarm S; Paris RM; Chunsutthiwat S; Premsri N; Namwat C; Bowonwatanuwong C; Li SS; Kaewkungkal J; Trichavaroj R; Churikanont N; de Souza MS; Andrews C; Francis D; Adams E; Flores J; Gurunathan S; Tartaglia J; O'Connell RJ; Eamsila C; Nitayaphan S; Ngauy V; Thongcharoen P; Kunasol P; Michael NL; Robb ML; Gilbert PB; Kim JH
    J Infect Dis; 2013 Apr; 207(8):1195-205. PubMed ID: 22837492
    [TBL] [Abstract][Full Text] [Related]  

  • 19. AIDS vaccine development: the long and winding road.
    Garber DA; Feinberg MB
    AIDS Rev; 2003; 5(3):131-9. PubMed ID: 14598562
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Support for the RV144 HIV vaccine trial.
    AIDS Vaccine Advocacy Coalition
    Science; 2004 Jul; 305(5681):177-80; author reply 177-80. PubMed ID: 15250069
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.